Connect Biopharma Presents CBP-201 Target Engagement and Immune Modulation Data at the Society for Investigative Dermatology Annual Conference
May 17 2022 - 4:05PM
Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect
Biopharma" or the “Company”), a global clinical-stage
biopharmaceutical company dedicated to improving the lives of
patients with chronic inflammatory diseases through the development
of therapies derived from T cell-driven research will be presenting
data describing the immunological profile of CBP-201 based on
preclinical experiments, demonstrating reductions in clinically
validated biomarkers of Th2-driven inflammation. Additionally, the
Company will be reporting distinct binding epitopes, higher binding
affinity, and increased potency demonstrating improved target
engagement properties with CBP-201 compared to dupilumab. The data
will be presented in a poster at the Society for Investigative
Dermatology Annual Conference, May 18-21 at the Oregon Convention
Center, Portland, Oregon.
Poster Presentation Details
Title: CBP-201, a novel and differentiated
IL-4Ra targeting antibody being evaluated in Th2 inflammatory
diseases
Presented by: Paul A. Smith, VP, Discovery
Biology, Connect Biopharma
The poster is available on the Presentations and Publications
section of the Company’s website:
https://www.connectbiopharm.com/our-science/presentations-and-publications/.
About Atopic DermatitisAtopic
dermatitis (AD), which has an estimated lifetime prevalence of up
to 20% and is increasing globally, is the most commonly diagnosed
chronic inflammatory skin disorder. It is characterized by skin
barrier disruption and immune dysregulation. In the United States,
it is estimated that 26.1 million people have AD, of which 6.6
million have moderate-to-severe disease. Estimates of prevalence of
AD in China show an increase over time and recent longitudinal
studies have reported a dermatologist-diagnosed prevalence of 7.8%
in Chinese outpatients visiting tertiary hospitals. Further, over
58% of adults with moderate-to-severe AD have disease that
physicians consider to be inadequately controlled by approved
therapeutic modalities, including topical anti-inflammatory agents
and systemic agents.
About CBP-201CBP-201,
discovered internally using Connect Biopharma's proprietary Immune
Modulation Technology Platform, is an antibody designed to target
interleukin-4 receptor alpha (IL-4Rα), which is a validated target
for the treatment of several inflammatory diseases, including
atopic dermatitis (AD). CBP-201 was well tolerated and showed
evidence of clinical activity in a Phase 2b clinical trial
(NCT04444752) in adult patients with moderate-to-severe atopic
dermatitis, suggesting a potential for a differentiated efficacy
profile compared with data from clinical trials of the current
biologic standard of care therapy. CBP-201 is also being evaluated
in a China specific pivotal trial in adults with moderate-to-severe
atopic dermatitis (NCT05017480); and in a Phase 2b trial in adult
patients with moderate-to-severe persistent asthma
(NCT04773678).
About Connect Biopharma Holdings
LimitedConnect Biopharma is a global, clinical-stage
biopharmaceutical company dedicated to improving the lives of
patients with inflammatory diseases through the development of
therapies derived from T cell-driven research. It is building a
rich pipeline of internally-designed, wholly-owned, small molecules
and antibodies using functional cellular assays with T cells to
screen and discover potent product candidates against validated
immune targets. Its lead product candidate, CBP-201, is an antibody
designed to target interleukin-4 receptor alpha (IL-4Rα) in
development for the treatment of atopic dermatitis (AD) and asthma.
The Company’s second most advanced product candidate, CBP-307, is a
modulator of a T-cell receptor known as S1P1 in development for the
treatment of UC. Clinical development has begun for its third
product candidate, CBP-174, a peripherally acting antagonist of
histamine receptor 3, for the treatment of pruritus associated with
AD.
With operations in the United States and China,
Connect Biopharma is building a rich global pipeline of molecules
and antibodies targeting several aspects of T cell biology. For
additional information, please visit
www.connectbiopharm.com.
FORWARD-LOOKING
STATEMENTSConnect Biopharma cautions that statements
included in this press release that are not a description of
historical facts are forward-looking statements. Words such as
"may," "could," "will," "would," "should," "expect," "plan,"
"anticipate," "believe," "estimate," "intend," "predict," "seek,"
"contemplate," “look forward,” "potential," "continue" or "project"
or the negative of these terms or other comparable terminology are
intended to identify forward-looking statements. These statements
include statements regarding the Company’s plans to advance the
development of its product candidates, the potential of such
product candidates, including to achieve any benefit or profile,
trends within the ulcerative colitis population, and partnerships
for the future development of CBP-307. The inclusion of
forward-looking statements shall not be regarded as a
representation by Connect Biopharma that any of its plans will be
achieved. Actual results may differ from those set forth in this
release due to the risks and uncertainties inherent in the Connect
Biopharma business and other risks described in the Company's
filings with the Securities and Exchange Commission (“SEC”),
including the Company’s Annual Report on Form 20-F filed with the
SEC on March 31, 2022, and its other reports. Investors are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and Connect
Biopharma undertakes no obligation to revise or update this news
release to reflect events or circumstances after the date hereof.
Further information regarding these and other risks is included in
Connect Biopharma's filings with the SEC which are available from
the SEC’s website (www.sec.gov) and on Connect Biopharma’s website
(www.connectbiopharm.com) under the heading "Investors." All
forward-looking statements are qualified in their entirety by this
cautionary statement. This caution is made under the safe harbor
provisions of Section 21E of the Private Securities Litigation
Reform Act of 1995.
IR/PR Contacts: Lazar FINN
Partners David Carey (IR) T: +1-(212)
867-1768david.carey@finnpartners.comGlenn Silver
(Media)T:
+1-(973)-818-8198glenn.silver@finnpartners.com
Corporate
Contacts:info@connectpharm.com
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From Sep 2023 to Sep 2024